{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T22:37:05Z","timestamp":1781995025922,"version":"3.54.5"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100021716","name":"University of Paris","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021716","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>In cases of maternal primary infection with cytomegalovirus (CMV-MPI) maternal treatment with oral valaciclovir 8 g\/day has been shown to reduce the risk of fetal infection. The pharmacological profile of this high dosage during pregnancy is not yet known.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To quantify maternal-fetal exposure to valaciclovir 8 g\/day in a population pharmacokinetic (popPK) study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Between October 2019 and April 2023, pregnant women referred for CMV-MPI were offered to participate following: (i) CMV-MPI &amp;lt;14 weeks of gestation; (ii) acceptance of valaciclovir 8 g\/day; and (iii) consent for amniocentesis. Amniotic fluid was tested for (i) CMV PCR for prenatal diagnosis; and (ii) dosage of aciclovir concentration (the active form of valaciclovir). Maternal serum levels of aciclovir were also measured. Aciclovir assays in both compartments were used for popPK analysis. Pharmacokinetics were described using non-linear mixed-effect modelling.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We prospectively included 119 women with their 122 fetuses. CMV-MPI occurred at a median of 3.0 (range: \u221212; +\u200a14) weeks of gestation. CMV-infected pregnant women were treated at a median of 12.3 (range: 4.6\u201321.4) weeks of gestation for a median duration of 35 days (range: 7\u201390 days). Median pharmacokinetic parameters (Cmin, Cmax and AUC0\u201324) were all successfully defined in both maternal blood and amniotic fluid compartments. No differences in aciclovir exposure were observed between infected (n\u200a=\u200a12, 9.8%) and non-infected fetuses. Simulations showed that after a last maternal dose, aciclovir concentration would be undetectable in the amniotic fluid after 43\u201347 h.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In this popPK study, maternal and fetal pharmacokinetics were established using in vivo data. The results provide a better understanding of how this fetal therapy works.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkae470","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T09:29:57Z","timestamp":1736933397000},"page":"760-766","source":"Crossref","is-referenced-by-count":5,"title":["Quantification of maternal and fetal valaciclovir exposure in a pharmacokinetic study of cytomegalovirus-infected pregnant women treated to prevent vertical transmission"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7510-9364","authenticated-orcid":false,"given":"Valentine","family":"Faure-Bardon","sequence":"first","affiliation":[{"name":"URP 7328 Federation for Research into Innovative Explorations and Therapeutics in Utero, University of Paris-Cit\u00e9 , Paris ,","place":["France"]},{"name":"Department of Gynecology and Obstetrics, Piti\u00e9 Salp\u00e9tri\u00eare Hospital, APHP, Sorbonne University , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na\u00efm","family":"Bouazza","sequence":"additional","affiliation":[{"name":"URP 7323 Pharmacology and Therapeutic Evaluation in Children and Pregnant Women, University of Paris-Cit\u00e9 , Paris ,","place":["France"]},{"name":"Unit\u00e9 de Recherche Clinique Necker Cochin, AP-HP , Paris ,","place":["France"]},{"name":"CIC-1419 Inserm, Cochin-Necker , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihem","family":"Benaboud","sequence":"additional","affiliation":[{"name":"URP 7323 Pharmacology and Therapeutic Evaluation in Children and Pregnant Women, University of Paris-Cit\u00e9 , Paris ,","place":["France"]},{"name":"Department of Clinical Pharmacology, Cochin Hospital, AP-HP, University of Paris-Cit\u00e9 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frantz","family":"Foissac","sequence":"additional","affiliation":[{"name":"URP 7323 Pharmacology and Therapeutic Evaluation in Children and Pregnant Women, University of Paris-Cit\u00e9 , Paris ,","place":["France"]},{"name":"Unit\u00e9 de Recherche Clinique Necker Cochin, AP-HP , Paris ,","place":["France"]},{"name":"CIC-1419 Inserm, Cochin-Necker , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steeve","family":"Rouillon","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Cochin Hospital, AP-HP, University of Paris-Cit\u00e9 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3950-7728","authenticated-orcid":false,"given":"L\u00e9o","family":"Froelicher-Bournaud","sequence":"additional","affiliation":[{"name":"URP 7323 Pharmacology and Therapeutic Evaluation in Children and Pregnant Women, University of Paris-Cit\u00e9 , Paris ,","place":["France"]},{"name":"Department of Clinical Pharmacology, Cochin Hospital, AP-HP, University of Paris-Cit\u00e9 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Leruez-Ville","sequence":"additional","affiliation":[{"name":"URP 7328 Federation for Research into Innovative Explorations and Therapeutics in Utero, University of Paris-Cit\u00e9 , Paris ,","place":["France"]},{"name":"Virology Laboratory, Necker-Enfants Malades Hospital, APHP, University of Paris-Cit\u00e9 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Guilleminot","sequence":"additional","affiliation":[{"name":"URP 7328 Federation for Research into Innovative Explorations and Therapeutics in Utero, University of Paris-Cit\u00e9 , Paris ,","place":["France"]},{"name":"Virology Laboratory, Necker-Enfants Malades Hospital, APHP, University of Paris-Cit\u00e9 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Lui","sequence":"additional","affiliation":[{"name":"URP 7323 Pharmacology and Therapeutic Evaluation in Children and Pregnant Women, University of Paris-Cit\u00e9 , Paris ,","place":["France"]},{"name":"CIC-1419 Inserm, Cochin-Necker , Paris ,","place":["France"]},{"name":"Department of Clinical Pharmacology, Cochin Hospital, AP-HP, University of Paris-Cit\u00e9 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Tr\u00e9luyer","sequence":"additional","affiliation":[{"name":"URP 7323 Pharmacology and Therapeutic Evaluation in Children and Pregnant Women, University of Paris-Cit\u00e9 , Paris ,","place":["France"]},{"name":"Unit\u00e9 de Recherche Clinique Necker Cochin, AP-HP , Paris ,","place":["France"]},{"name":"CIC-1419 Inserm, Cochin-Necker , Paris ,","place":["France"]},{"name":"Department of Clinical Pharmacology, Cochin Hospital, AP-HP, University of Paris-Cit\u00e9 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Ville","sequence":"additional","affiliation":[{"name":"URP 7328 Federation for Research into Innovative Explorations and Therapeutics in Utero, University of Paris-Cit\u00e9 , Paris ,","place":["France"]},{"name":"Department of Obstetrics, Fetal-Medicine, and Surgery, Necker-Enfants Malades Hospital, APHP, University of Paris-Cit\u00e9 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"key":"2025030423053806300_dkae470-B1","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/rmv.535","article-title":"Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection","volume":"17","author":"Kenneson","year":"2007","journal-title":"Rev Med Virol"},{"key":"2025030423053806300_dkae470-B2","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1093\/cid\/ciy1128","article-title":"Sequelae of congenital cytomegalovirus (cCMV) following maternal primary infection are limited to those acquired in the first trimester of pregnancy","volume":"69","author":"Faure-Bardon","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025030423053806300_dkae470-B3","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.ajog.2020.05.038","article-title":"Timing of primary maternal cytomegalovirus infection and rates of vertical transmission and fetal consequences","volume":"223","author":"Chatzakis","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"2025030423053806300_dkae470-B4","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S0140-6736(20)31868-7","article-title":"Valaciclovir to prevent vertical transmission of cytomegalovirus after maternal primary infection during pregnancy: a randomised, double-blind, placebo-controlled trial","volume":"396","author":"Shahar-Nissan","year":"2020","journal-title":"Lancet"},{"key":"2025030423053806300_dkae470-B5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ajog.2023.07.022","article-title":"The effect of valacyclovir on secondary prevention of congenital cytomegalovirus infection, following primary maternal infection acquired periconceptionally or in the first trimester of pregnancy. An individual patient data meta-analysis","volume":"230","author":"Chatzakis","year":"2024","journal-title":"Am J Obstet Gynecol"},{"key":"2025030423053806300_dkae470-B6","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/uog.23685","article-title":"Secondary prevention of congenital cytomegalovirus infection with valacyclovir following maternal primary infection in early pregnancy","volume":"58","author":"Faure-Bardon","year":"2021","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2025030423053806300_dkae470-B7","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1056\/NEJM199905133401903","article-title":"Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation","volume":"340","author":"Lowance","year":"1999","journal-title":"N Engl J Med"},{"key":"2025030423053806300_dkae470-B8","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/clpt.1993.196","article-title":"Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single-and multiple-dose administration to normal volunteers","volume":"54","author":"Weller","year":"1993","journal-title":"Clin Pharmacol Ther"},{"key":"2025030423053806300_dkae470-B9","doi-asserted-by":"publisher","first-page":"105614","DOI":"10.1016\/j.jcv.2023.105614","article-title":"Comparison of two serological screening strategies for cytomegalovirus primary infection in the first trimester of pregnancy","volume":"169","author":"Fourgeaud","year":"2023","journal-title":"J Clin Virol"},{"key":"2025030423053806300_dkae470-B10","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/uog.24753","article-title":"Renal toxicity of high-dosage valacyclovir for secondary prevention of congenital cytomegalovirus infection: a dose regimen-related issue","volume":"58","author":"Ville","year":"2021","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2025030423053806300_dkae470-B11","doi-asserted-by":"publisher","first-page":"e01426-20","DOI":"10.1128\/AAC.01426-20","article-title":"Population pharmacokinetics of intravenous and oral acyclovir and oral valacyclovir in pediatric population to optimize dosing regimens","volume":"64","author":"Abdalla","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2025030423053806300_dkae470-B12","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/uog.23724","article-title":"Acute kidney injury after valacyclovir administration for prevention of congenital cytomegalovirus infection","volume":"58","author":"Schurder","year":"2021","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2025030423053806300_dkae470-B13","doi-asserted-by":"publisher","first-page":"F280","DOI":"10.1136\/adc.2007.119230","article-title":"Congenital cytomegalovirus: association between dried blood spot viral load and hearing loss","volume":"93","author":"Walter","year":"2008","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"2025030423053806300_dkae470-B14","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1093\/jac\/dkh244","article-title":"Pharmacokinetics of valaciclovir","volume":"53","author":"MacDougall","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"2025030423053806300_dkae470-B15","doi-asserted-by":"publisher","first-page":"462.e1","DOI":"10.1016\/j.ajog.2016.04.003","article-title":"In utero treatment of congenital cytomegalovirus infection with valacyclovir in a multicenter, open-label, phase II study","volume":"215","author":"Leruez-Ville","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"2025030423053806300_dkae470-B16","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1111\/j.1471-0528.2007.01308.x","article-title":"Maternal administration of valaciclovir in symptomatic intrauterine cytomegalovirus infection","volume":"114","author":"Jacquemard","year":"2007","journal-title":"BJOG"},{"key":"2025030423053806300_dkae470-B17","doi-asserted-by":"publisher","first-page":"496","DOI":"10.2174\/1381612825666190319102812","article-title":"Methodological approaches to evaluate fetal drug exposure","volume":"25","author":"Bouazza","year":"2019","journal-title":"Curr Pharm Des"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/3\/760\/61439383\/dkae470.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/3\/760\/61439383\/dkae470.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T23:05:43Z","timestamp":1741129543000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/3\/760\/7954202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":17,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,1,15]]},"published-print":{"date-parts":[[2025,3,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae470","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,1,15]]}}}